🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

120 results for “administration” Clear

  1. Erbitux 5 mg/mL solution for infusion, Ficlatuzumab, Ficlatuzumab, The corresponding placebo for this study is 0.9% Sodium Chloride injection for intravenous administration and this will be provided by the study site (and reimbursed by the Sponsor).

    Lacuna Pharma Pty Ltd

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 3 small molecule active

    1 trial

  2. ION 682884, Placebo injection, 0.8 ml (is a sterile, preservative-free, parenteral solution of sodium chloride and riboflavin in Water for Injection) for subcutaneous administration

    IONIS PHARMACEUTICALS INC

    Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

    phase 3 small molecule active

    1 trial

  3. Intravenous methylene blue administration

    Hospital Authority, Hong Kong

    Severe Sepsis

    phase 3 small molecule active

    1 trial

  4. Levosimendan, The levosimendan placebo drug product is an immediate-release dosage form for oral administration.

    TENAX THERAPEUTICS, INC.

    Pulmonary Hypertension (PH) with Heart Failure with preserved left ventricular ejection fraction (PH-HFpEF)

    phase 3 small molecule active

    1 trial

  5. MITAPIVAT, MITAPIVAT, "Placebo to Match Mitapivat Tablets, 5 mg and 20 mg, are supplied as film-coated, blue, round tablets for oral administration Placebo to Match Mitapivat Tablets, 50 mg or 100 mg, are supplied as film-coated, blue, oblong tablets for oral administration. Placebo to Match Mitapivat Granules, 1 mg, are supplied as film-coated, white, round granules for oral administration", MITAPIVAT

    Lacuna Pharma Pty Ltd

    Anemia in subjects with sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  6. NPC-11 for intravenous or oral administration.

    Belpharma s.a.

    Apnea of Prematurity

    phase 3 small molecule completed

    1 trial

  7. ONDANSETRON ZYDUS 8 mg, comprimé orodispersible, Jakavi 5 mg tablets, EMEND 125 mg+80 mg hard capsules, Jakavi 15 mg tablets, Jakavi 20 mg tablets, PALONOSETRON, NETUPITANT, Akynzeo 300 mg/0.5 mg hard capsules, Selinexor placebo for 20 mg tablets formulated for oral administration., Jakavi 10 mg tablets, SELINEXOR, ONDANSETRON

    Karyopharm Therapeutics Inc

    Treatment naïve patients with MF

    phase 3 small molecule active

    1 trial

  8. PL1 - Placebo to match losmapimod tablets are tablets for oral administration and visually match the active losmapimod tablets, 15 mg., Losmapimod

    Fulcrum Therapeutics

    Facioscapulohumeral Muscular Dystrophy (FSHD)

    phase 3 small molecule active

    1 trial

  9. Placebo is a sterile solution in a single use prefilled syringe (PFS) intended for subcutaneous administration., Skyrizi 150 mg solution for injection in pre-filled syringe, Sonelokimab, Sonelokimab

    MoonLake Immunotherapeutics

    psoriatic arthritis

    phase 3 small molecule active

    1 trial

  10. Placebo tablets to match S95032 drug product are supplied as film-coated tablets for oral administration., S95032/AG-881, S95032/AG-881

    Ningbo Cancer Hospital

    ​​IDH-mutant grade 2 or 3 astrocytoma​

    phase 3 small molecule active

    1 trial

  11. Placebo tablets to match S95032 drug product are supplied as white to off-white, round (10 mg) and white to off-white oblong (40 mg) film-coated tablets for oral administration., S95032/AG-881, S95032/AG-881

    The George Institute

    Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation

    phase 3 small molecule active

    1 trial

  12. Powder for reconstitution for enteral administration

    Lacuna Pharma Pty Ltd

    Intestinal Malabsorption

    phase 3 small molecule active

    1 trial

  13. Powder for reconstitution for enteral administration

    Lacuna Pharma Pty Ltd

    Intestinal Malabsorption

    phase 3 small molecule active

    1 trial

  14. SELINEXOR, Selinexor placebo for 20 mg tablets is formulated for oral administration. selinexor placebo tablets are film coated bi-convex round tablets

    Karyopharm Therapeutics Inc

    endometrial cancer

    phase 3 small molecule active

    1 trial

  15. Sonelokimab, Placebo is a sterile solution in a single use prefilled syringe (PFS) intended for subcutaneous administration

    MoonLake Immunotherapeutics

    hidradenitis suppurativa (HS)

    phase 3 small molecule active

    1 trial

  16. Sonelokimab, Placebo is a sterile solution in a single use prefilled syringe (PFS) intended for subcutaneous administration

    MoonLake Immunotherapeutics

    hidradenitis suppurativa (HS)

    phase 3 small molecule active

    1 trial

  17. Sonelokimab, Placebo is a sterile solution in a single use prefilled syringe (pfs) intended for subcutaneous administration

    MoonLake Immunotherapeutics

    Psoriatic arthritis

    phase 3 small molecule active

    1 trial

  18. UI022 or UI023 and co-administration of matching placebo

    United Therapeutics Europe Ltd

    Peripheral Arterial Disease

    phase 3 small molecule completed

    1 trial

  19. Vidaza 25 mg/ml powder for suspension for injection, AG-120/S95031 250mg film-coated tablet, Placebo to Match AG-120 Tablet, 250 mg, is supplied as a film-coated tablet for oral administration.

    The George Institute

    Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

    phase 3 small molecule active

    1 trial

  20. A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients who are BCG Naïve or Received Incomplete BCG Treatment

    Shanghai Antengene Corporation Limited

    Non-muscle invasive bladder cancer (NMIBC)

    phase 2 other active

    1 trial

  21. A phase I study evaluating safety and efficacy of Hepatic Intra- Arterial administration of ipilimumab in combination with Intra- venous nivolumab for advanced Hepatocellular carcinoma (HIPANIV)

    The George Institute

    Advanced hepatocellular carcinoma

    phase 2 other active

    1 trial

  22. ALN-TTRSC (revusiran) for subcutaneous administration

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

  23. AS01 adjuvant (0.5 mL intramuscular)

    Hospital Authority, Hong Kong

    Immune System Responses and Trained Immunity After AS01 Administration

    phase 2 mab active

    1 trial

  24. Administration of experimental treatment association (sotorasib, panitumumab 5FU)

    NORTHWEST BIOTHERAPEUTICS INC

    Colorectal Carcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources